SkinCeuticals Unveils A.G.E. Interrupter Ultra Serum, Tailored for Weight Loss Medication Users
SkinCeuticals, the renowned medical-grade skincare brand, has unveiled its highly anticipated product of 2025 – the A.G.E. Interrupter Ultra Serum. This groundbreaking serum has been uniquely developed and tested on users of GLP-1 weight loss medications.
The brand has astutely recognized a burgeoning market opportunity, with JP Morgan Research forecasting that as many as 30 million Americans could be using weight loss drugs by 2030. The A.G.E. Interrupter Ultra Serum’s double-patented formula tackles skin laxity, a common side effect of rapid weight loss, delivering clinically proven results of up to 18% visible skin lifting within a span of 12 weeks.
The potent serum brings together Flavo-Proxylane™, Rhamnose, and Gentiana Lutea Root Extract, targeting four key areas: the forehead, cheeks, jawline, and neck.
“We are laser-focused on medical trends driving consumers to clinics, and that’s how we got the idea to test this A.G.E. Interrupter Ultra Serum with GLP-1 patients,” said Tara Pyle, SkinCeuticals’ General Manager.
While the serum was formulated with weight loss drug users in mind, it also benefits anyone experiencing sagging skin due to natural aging processes. Clinical studies have shown a 20% reduction in skin laxity when the serum is used as part of an integrated regimen, which includes the brand’s A.G.E. Interrupter Advanced Cream and ultrasound procedures.
The A.G.E. Interrupter Ultra Serum was launched on August 4, 2025, and is projected to drive significant new customer acquisition for the brand.
Source: wwd.com